Table 3.
The resistant phenotypes of Shigella serotypes
| Drugs | Serotype | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| F1a (n = 59) | F1b (n = 8) | F1c (n = 1) | F2a (n = 130) | F2b (n = 30) | F2ab (n = 9) | F3a (n = 15) | F4 (n = 9) | F4c (n = 121) | F5 (n = 2) | F5a (n = 1) | F5b (n = 20) | F6 (n = 2) | Fx (n = 60) | Fy (n = 19) | Flexneri (n = 486) | Sonnei (n = 40) | P | |
| CFZ | 4 (6·8) | 1 (12·5) | 0 | 9 (6·9) | 4 (13·3) | 1 (11·1) | 1 (6·7) | 0 | 5 (3·8) | 0 | 0 | 1 (5) | 0 | 2 (3·3) | 2 (10·5) | 30 (6·2) | 7 (17·5) | 0·007 |
| CTX | 2 (3·4) | 0 | 0 | 5 (3·8) | 3 (10) | 1 (11·1) | 0 | 0 | 2 (1·5) | 0 | 0 | 0 | 0 | 1 (1·6) | 1 (5·3) | 15 (3·1) | 2 (5) | n.s. |
| AMC | 57 (96·6) | 4 (50) | 1 (100) | 127 (97·7) | 30 (100) | 8 (88·8) | 14 (93·3) | 9 (100) | 118 (97·7) | 2 (100) | 1 (100) | 17 (85) | 2 (100) | 60 (100) | 18 (94·7) | 468 (96·1) | 1 (2·5) | 0·000 |
| AMP | 57 (96·6) | 4 (50) | 1 (100) | 127 (97·7) | 30 (100) | 9 (100) | 14 (93·3) | 9 (100) | 120 (99·2) | 2 (100) | 1 (100) | 20 (100) | 2 (100) | 58 (96·7) | 18 (94·7) | 472 (97·1) | 10 (25) | 0·000 |
| GM | 2 (3·4) | 0 | 0 | 4 (3·1) | 0 | 0 | 0 | 0 | 4 (3) | 0 | 0 | 0 | 0 | 2 (3·3) | 0 | 12 (2·4) | 12 (30) | 0·000 |
| C | 57 (96·6) | 7 (87·5) | 1 (100) | 125 (96·2) | 30 (100) | 9 (100) | 15 (100) | 9 (100) | 118 (97·7) | 2 (100) | 1 (100) | 20 (100) | 2 (100) | 60 (100) | 18 (94·7) | 474 (97·5) | 8 (20) | 0·000 |
| TE | 59 (100) | 8 (100) | 1 (100) | 128 (98·5) | 30 (100) | 9 (100) | 15 (100) | 9 (100) | 121 (100) | 2 (100) | 1 (100) | 20 (100) | 2 (100) | 58 (96·7) | 19 (100) | 482 (99·2) | 39 (97·5) | n.s. |
| SMZ | 41 (69·5) | 4 (50) | 0 | 100 (77) | 21 (70·0) | 7 (77·8) | 13 (86·7) | 5 (55·5) | 108 (89·3) | 1 (50) | 1 (100) | 15 (75) | 2 (100) | 42 (70) | 14 (73·7) | 374 (77·0) | 39 (97·5) | 0·002 |
| PB | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (5·3) | 1 (0·2) | 0 | n.s. |
| NAL | 57 (96·6) | 7 (87·5) | 1 (100) | 126 (97) | 30 (100) | 9 (100) | 15 (100) | 9 (100) | 118 (97·7) | 2 (100) | 1 (100) | 20 (100) | 2 (100) | 60 (100) | 18 (94·7) | 475 (97·7) | 40 (100) | n.s. |
| PI | 57 (96·6) | 7 (87·5) | 1 (100) | 126 (97) | 30 (100) | 9 (100) | 15 (100) | 9 (100) | 118 (97·7) | 2 (100) | 1 (100) | 20 (100) | 2 (100) | 60 (100) | 18 (94·7) | 475 (97·7) | 40 (100) | n.s. |
| CIP | 21 (35·6) | 1 (12·5) | 0 | 64 (49·2) | 8 (26·7) | 1 (11·1) | 0 | 2 (22·2) | 22 (18·3) | 0 | 0 | 0 | 0 | 13 (21·7) | 3 (15·8) | 135 (27·8) | 2 (5) | 0·002 |
| F | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (5·3) | 1 (0·2) | 0 | n.s. |
| TOB | 5 (8·5) | 1 (12·5) | 0 | 9 (6·9) | 4 (13·3) | 1 (11·1) | 1 (6·7) | 0 | 9 (7·6) | 0 | 0 | 1 (5) | 0 | 4 (6·7) | 1 (5·3) | 36 (7·4) | 2 (5) | n.s. |
AMP, Ampicillin; AMC, amoxicillin; C, chloramphenicol; CFZ, cefamezin; CIP, ciprofloxacin; CTX, cefotaxime; F, furazolidone; GM, gentamicin; NAL, nalidixic acid; PB, polymyxin B; PI, pipemidic acid; SMZ, co-trimoxazole; TE, tetracycline; TOB, tobramycin.
n, Total number of strains; n.s., not significant.
Numbers within parentheses indicate percentage.